Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

美国食品药品监督管理局 (FDA) 已批准对可手术的 IIA 期至 IIIB 期 NSCLC 患者进行新辅助 nivolumab 联合化疗，随后进行辅助 nivolumab 治疗，这一结果得到了 2023 年 ESMO 大会上公布的 3 期 ...

"主要的信息是，在免疫检查点阻断后，癌症免疫治疗中的代谢适应可能是相关的，"Toni K. Choueiri医学博士说。代谢过程是机体内维持生命所必需的化学反应，如将食物转化为能量以运行细胞过程。

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final ...

Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study. Efficacy outcomes with belzutifan versus everolimus by ...

Patients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.